Neurodegenerative
disease such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease,
amyotrophic lateral sclerosis, frontotemporal dementia, and the spinocerebellar
ataxias is major health threat specifically in the elderly population.
Currently, the disease diagnosis and progression is tracked through the clinical
estimation which only gives a rough estimate of the disease severity. So the biomarkers
serve as an essential tool in the disease diagnosis and disease progression. High-throughput
omics-based technologies have facilitated the discovery of new biomarkers. The
analytic methods underlying the basic omics-based technologies, genomics,
transcriptomics, and metabolomics are now been extensively useful in the identification
of novel biomarkers. These new candidate biomarkers are helpful in the clinical
management of neurological disorders.
Keywords: Genomics, Metabolomics, Neurodegenerative disease, Omics, Proteomics, Transcriptomics.
